Strides Pharma Science Limited issued guidance on the Cost of Acquisition (COA) for its shareholders following the demerger, explaining how to split the COA between Strides and Onesource shares. The guidance comes after the approval of the demerger scheme by the NCLT.
As part of the Scheme, Strides Pharma will demerge its Identified Contract Development and Manufacturing Organisation (CDMO) Business and Soft Gelatin Business (Demerged Undertaking 1) into Onesource Specialty Pharma Limited (Onesource).
Additionally, Steriscience Specialities Private Limited will demerge its CDMO business (Demerged Undertaking 2) into Onesource.
Shareholders of Strides, whose names appear in the Register of Members as of the Record Date, December 6, 2024, will receive one fully paid-up equity share of Onesource for every two fully paid-up shares of Strides.
For tax purposes, Strides shareholders are advised to allocate their COA between Strides and Onesource as follows: 89.35% for Strides and 10.65% for Onesource.
For example, if a shareholder holds 60 shares of Strides with an acquisition cost of ₹1,000 per share, they would have a total acquisition cost of ₹60,000.
Upon receiving 30 shares of Onesource, their proportionate COA for Onesource would be ₹6,390 (₹213 per share) and for Strides, it would be ₹53,610 (₹893.50 per share).
On December 12, 2024, Strides Pharma Science’s share price traded 3.08% lower at ₹715 at 12:15 PM on the NSE. The stock opened at ₹747, higher than ₹736.85 at the previous close.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
